Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Sanofi Suffers 6.6% Decline in Japan Revenues
February 22, 2016
- Fuso Voluntarily Recalls Maltose-Lactated Ringer’s Inj. and Replas Injection Due to Mislabeling
February 22, 2016
- Ferring Revs Up for Full-Fledged Foray into GI Market, Eyes Japan Sales of €300 Million in 2020
February 19, 2016
- Fujifilm Begins US PI Study for Cancer Drug FF-10502
February 19, 2016
- Sakigake: Now and Future (3) - Astellas’s FLT3 Inhibitor for AML Receives Designation, but Other Companies Trailing
February 19, 2016
- US Merck to Sell Daiichi Sankyo’s Lixiana in 13 European Countries
February 18, 2016
- JCR to Roll Out Cell Therapy Temcell on Feb. 24; Medipal to Be Exclusive Distributor
February 18, 2016
- Genzyme Japan to Be Merged into Sanofi in July
February 17, 2016
- Eisai, Sysmex Link Up in Next-Gen Diagnostic Reagents for Dementia
February 16, 2016
- Shionogi Joins Cambridge Therapeutic Consortium
February 16, 2016
- Asahi Kasei, Pfizer Wind Up Recomodulin Copromotion Scheme
February 16, 2016
- Otsuka’s Pharma Sales Down Nearly 15% in 2015
February 15, 2016
- Pfizer’s Metformin 500 mg Fails to Clear Test, Shipment Suspended
February 15, 2016
- Astellas Completes Acquisition of Ocata
February 15, 2016
- Alecensa Japan PIII Trial Halted Early for Benefit
February 12, 2016
- Lilly’s Japan Sales Slip 2% to US$1.9 Billion in 2015
February 12, 2016
- Sakigake: Now and Future (2) - Shionogi Aims to Submit Application for Novel Flu Drug as Early as FY2017
February 12, 2016
- New CSL Japan Chief Eager to See Annual Sales of 40 Billion Yen in 5 Years
February 10, 2016
- Asahi Kasei President to Step Down over Piling Data Scandal
February 10, 2016
- Daiichi Sankyo to Close UK Development Unit
February 10, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…